Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Clinical Trial Evaluating Ipilimumab and Nivolumab in Combination for the Treatment of Rare Gastrointestinal, Neuro-Endocrine and Gynaecological Cancers

Next Previous
Trial Profile

A Phase II Clinical Trial Evaluating Ipilimumab and Nivolumab in Combination for the Treatment of Rare Gastrointestinal, Neuro-Endocrine and Gynaecological Cancers

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Biliary cancer; Bronchial cancer; Carcinoid tumour; Carcinoma; Cholangiocarcinoma; Clear cell sarcoma; Duodenal cancer; Gallbladder cancer; Gastrointestinal cancer; Gynaecological cancer; Intestinal cancer; Leiomyosarcoma; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer; Sarcoma; Squamous cell cancer; Uterine cancer
  • Focus Therapeutic Use

Most Recent Events

  • 24 Jul 2024 Status changed from active, no longer recruiting to completed.
  • 12 Jun 2020 Results of subgroup analysis (n=29) of outcome of the neuroendocrine cohort of the CA209-538 clinical trial published in the Clinical Cancer Research
  • 31 May 2020 Results (n=41 ,advanced rare gynecological malignancies) presented at the 56th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top